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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.026The discovery of thewide plasticity ofmost cell typesmeans that it is now possible to produce virtually any cell
type in vitro. This concept, developedbecauseof thepossibility of reprogramming somatic cells toward induced
pluripotent stem cells, provides the opportunity to produce specialized cells that harbormultiple phenotypical
traits, thus integrating genetic interindividual variability. The ﬁeld of hepatology has exploited this concept,
and hepatocyte-like cells can now be differentiated from induced pluripotent stem cells. This review discusses
the choice of somatic cells to be reprogrammed by emergent new and nonintegrative strategies, as well as the
application of differentiated human induced pluripotent stem cells in hepatology, including liver develop-
ment, diseasemodeling, host-pathogen interactions, and drugmetabolism and toxicity. The actual consensus
is that hepatocyte-like cells generated in vitropresent an immature phenotype. Currently, developed strategies
used to resolve this problem, such as overexpression of transcription factors, mimicking liver neonatal and
postnatal modiﬁcations, and re-creating the three-dimensional hepatocyte environment in vitro and in vivo,
are also discussed. (Am J Pathol 2014, 184: 332e347; http://dx.doi.org/10.1016/j.ajpath.2013.09.026)Supported by the VaCaRMe project funded by the Région Pays de la
Loire (K.S.T., A.C., B.C.) and the FP7 Marie Curie IRG 277188/IPSMILD
(K.S.T.).
This article is part of a review series on liver pathobiology.The process of obtaining hepatocytes from human somatic
cells requires several steps: isolation and reprogramming
toward human induced pluripotent stem cells (hiPSCs),
followed by differentiation and maturation of hiPSCs into
hepatocyte-like cells (HLCs) (Figure 1). Each of these steps
has been the result of recent scientiﬁc breakthroughs that are
continuously evolving at a fast pace. The goals of this re-
view are to provide an overview of these different steps,
identify areas of improvement, and explore how these steps
will promote the emergence of efﬁcient models for research
and clinical applications in hepatology.
Reprogramming Patient-Speciﬁc Somatic Cells:
How, What, and Why?
Current Reprogramming Strategies
Since the proof of concept that human somatic cells can be
reprogrammed toward hiPSCs in 2007,1,2 two major aspectsstigative Pathology.
.are continuously under investigation: how to induce somatic
cell reprogramming and which somatic cells to reprogram.
As initially described, cell reprogramming required the
ectopic expression of transcription factors, such as octamer-
binding transcription factor 4 (OCT4) and sex-determining
region Y-box 2 (SOX2) in combination with Kruppel-like
factor 4 (KLF4) and v-myc avian myelocytomatosis viral
oncogene homolog (MYC)1 or Nanog homeobox (NANOG)
and LIN28 Homolog A (Caenorhabditis elegans) (LIN28).2
Recent ﬁndings demonstrated that OCT4 and SOX2 could
be substituted by mesodermal and ectodermal lineage spec-
iﬁers to promote cell programming.3 To identify such fac-
tors, the authors considered that rather than being a
stable state, pluripotency resulted from a balance between
Figure 1 From human induced pluritpotent stem cells (hiPSC) toward
hepatocyte- like cells (HLC). 1: Type of procedures related to the source of
human somatic cells. 2: Methods for reprogramming human somatic cells
toward hiPSCs. 3: hiPSC characterization for validation. At this point,
genome editing from healthy hiPSCs is an option to generate new hiPSC
clones with the mutation of interest. 4: During their differentiation toward
HLCs, hiPSCs go through an intermediate stage known as speciﬁed hepatic
endoderm (typically FOXA2þ, HNF4aþ, AFP). 5: In parallel with HLC dif-
ferentiation, hiPSCs could be differentiated into other hepatic cell types to
study related pathologies or improve HLC maturation. 6: Once differenti-
ated, HLCs are characterized to evaluate their level of maturation. To
compare such criteria among protocols, standardized procedures are
preferable.
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The American Journal of Pathology - ajp.amjpathol.orgdifferentiation programs because OCT4 and SOX2 promote
mesendodermal and ectodermal differentiation, respectively.
Their ﬁndings led to the identiﬁcation of GATA3 as a
mesendodermal lineage speciﬁer and the combination of
ZNF521, PAX6, and OTX2 as ectodermal lineage speciﬁers
strong enough to counterbalance the effect of GATA3.
Therefore, the identiﬁcation of such factors, which are able
to reprogram human somatic cells toward hiPSCs together
with KLF4 and MYC, admittedly with a low efﬁciency
(0.0002%), opens new perspectives on the mechanisms that
underlie pluripotency and the design of small molecules for
reprogramming. Finally, the Hanna group recently demon-
strated that the reprogramming efﬁciency of human somatic
cells could be greatly improved after silencing of the MBD3
protein, a subunit of the nucleosome remodeling and
deacetylation complex.4 The MBD3 and nucleosome
remodeling and deacetylation complex, which modulates
the DNA methylation state, including pluripotency gene
expression, was previously reported to block mouse somatic
cell reprogramming; however, its effects could be reversed
after MBD3 depletion.5
Reprogramming factors were initially expressed in human
somatic cells by retroviruses, which have drawbacks linked
to their integration into genomic DNA and to their potential
reexpression on hiPSC differentiation.6 To overcome these
issues, several groups have developed new strategies to
introduce reprogramming transcription factors in human
somatic cells, such as RNA-based Sendai virus, mRNA, and
episomal plasmid transfection with or without small mole-
cules. A major advance in human somatic cell reprogram-
ming has been recently published by Khan et al,7 who
delivered recombinant transcription factor proteins com-
plexed with cationic bolaamphiphile directly into cells. In
addition to classic factors such as NANOG, SOX2, and
KLF4, another factor added to their reprogramming cocktail
was nuclear receptor subfamily 5, group A, member 2 (alias
liver receptor homolog-1), a transcription factor that acts
upstream of OCT4 and has been reported to be capable of
participating in the reprogramming process.8 Reprogram-
ming efﬁciency was estimated at 0.05% and may probably
be enhanced with sequential introduction of reprogramming
factors as reported by Liu et al,9 with a fourfold increase in
efﬁciency in human skin ﬁbroblasts compared with simul-
taneous introduction of reprogramming factors. The absence
of genetic material combined with the simplicity of the
technique means that this procedure described by Khan
et al7 could possibly be a game changer in the reprogram-
ming ﬁeld in the near future.
Choice of Human Somatic Cells to Reprogram: One
Person’s Trash Is Another Person’s Treasure
Skin ﬁbroblasts remain the major somatic cell type used as a
cell source for generation of hiPSCs. In addition to being the
ﬁrst reprogrammed human cells, they are easily accessible
with a simple skin biopsy. Their relatively simple culture333
Figure 2 Culture and reprogramming of urine-derived progenitor cells
(UPC) toward hiPSCs. A: Before the ﬁrst passage, isolated UPCs formed
dense colonies of cells with a rice grain shape. B: Eight to 10 days after
reprogramming, UPCs underwent morphologic changes characteristic of
somatic cell reprogramming. C: Sixteen to 20 days after reprogramming,
colonies with morphologic aspects of hiPSCs were ready to be transferred
onto mouse embryonic ﬁbroblasts. Morphologic aspects of hiPSC colonies at
passage 8 after 4% paraformaldehyde ﬁxation (D) were positive for both
OCT4 (E) and SOX2 (F) after immunoﬂuorescent staining.
Gerbal-Chaloin et alconditions enable the production of cells in the large quan-
tities necessary for the reprogramming process and subse-
quent genetic and molecular tests needed to validate hiPSC
clones. However, skin biopsy has several downsides. For the
patient, it is an invasive act that can lead to scarring and may
have undesirable effects. For the research group, it requires
time-consuming administrative procedures to obtain
approval from the local institutional review board. Therefore,
several groups have developed techniques for reprogram-
ming alternative patient-speciﬁc somatic cells, such as blood
cells,10 amniotic tissue,11 or hair follicleederived keratino-
cytes.12 Recently, it was found that urine-derived progenitor
cells (UPC) can be isolated and ampliﬁed in vitro.13 In
addition to their intrinsic properties that allow for differen-
tiation into various cell types, such as urothelial cells, smooth
muscle cells, endothelial cells, or neurons among others,14
UPCs were successfully reprogrammed into hiPSCs.15
Moreover, because urine samples can be stored at least 24
hours at 4C before isolating UPCs,16 this technique is
convenient to obtain disease-speciﬁc somatic cells from
remote patients. In our hands, after 7 to 10 days of culture, we
were able to isolate UPCs from approximately 70% of donors
(nZ 28), including fresh and 24-hour stored urine samples
(n Z 56) (Figure 2A). Two rounds of ampliﬁcation were
enough to obtain cells for cell reprogramming with a single
round of nucleofection using episomal vectors coding for
OCT4, SOX2, KLF4, MYC, LIN28, and NANOG and a
nonepisomal vector coding for miR302/367.17 Cells under-
going morphologic changes were observed after 8 days of
reprogramming (Figure 2B), and colonies that resembled
hiPSC clones were picked after 16 to 20 days (Figure 2C) and
plated on mitotically inactive mouse embryonic ﬁbroblasts.
After several passages on mouse embryonic ﬁbroblasts, our
preliminary results indicated that UPC-derived hiPSCs
maintain their morphologic features (Figure 2D) and express
the pluripotent markers OCT4 (Figure 2E) and SOX2
(Figure 2F). Recently, UPCs were reprogrammed into
hiPSCs using a similar strategy.18 Thus, UPCs can be
considered as an attractive and easily accessible source of
human somatic cells for reprogramming. However, because
of the easy access of such cells combined with the explosion
of hiPSC research worldwide, ethical issues and communi-
cation with patients through informed consent will probably
have to be rethought in the near future. Discussions
addressing these concerns are currently lacking in scientiﬁc
reviews.19
Is Programming New Human Somatic Cells Always
Necessary?
The possibility of modeling patient-related disease in a Petri
dish has made hiPSCs a key player in the ﬁeld of cell biology.
However, if obtaining and reprogramming somatic cells are
getting easier with time, generating new hiPSC clones is far
from trivial: in addition to recruiting patients, numerous ge-
netic and molecular tests are required to validate new clones.334Such tests include karyotyping and evaluation of their ability
to differentiate into cells derived from the three germ layers
by direct differentiation and teratoma formation, which are
time-consuming and expensive procedures. Therefore, the
decision to generate new hiPSC clones as opposed to using
heterologous models or tumor cell lines must be carefully
considered, especially for studies that focus on monogenic
mutations regardless of the effect of the genomic environ-
ment. Recent ﬁndings in genome editing now offer an
exciting new alternative to somatic cell reprogramming.
Indeed, although the correction of disease-related mutations,
an obvious application of human genome editing, has been
demonstrated in diseases such as a1-antitrypsin deﬁciency,
20
the Cowan group has published proof-of-concept disease
models using site-directed mutations of 15 genes in human
cell lines or pluripotent stem cells.21 Once mutations were
induced, related disease phenotypes were recapitulated
in vitro after differentiation. In addition to inducing speciﬁc
mutations with transcription activatorelike effector nucle-
ases, the same group published soon thereafter a study that
found the possibility of editing the human genome with
higher efﬁciency by means of cluster regulatory interspaced
short palindromic repeats and cluster regulatory interspaced
short palindromic repeatseassociated technology.22 How-
ever, the latest technology still leads to numerous off-targetajp.amjpathol.org - The American Journal of Pathology
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such a model is highly attractive because hiPSC clones car-
rying the mutation of interest could now be easily and quickly
derived from control hiPSCs in a cost-effective manner
compared with the generation of new hiPSC clones. It is
worth noticing that this model also provides an isogenic
control, which may facilitate comparative studies, because
Kajiwara et al23 reported that genetic variations among do-
nors can affect the propensity of hiPSCs to differentiate to-
ward HLC.
Human iPSC Differentiation
What Are Differentiated HLCs?
Knowledge gathered through studies on liver development24
has provided biological cues to direct hiPSC differentiation
toward cells with hepatocyte features qualiﬁed as HLCs.
Brieﬂy, in response to speciﬁc inductive cues added to
culture medium, hiPSCs sequentially acquired characteristics
of deﬁnitive endoderm with the expression of forkhead box 2
(FOXA2), sex determining region Y-box (SOX17), and
GATA binding protein 4 (GATA4); speciﬁed endoderm with
the expression of T-BOX 3 and hepatocyte nuclear factor 4a
(HNF4a); hepatic progenitors expressing a-fetoprotein
(AFP); and ﬁnally HLCs displaying numerous hepatocyte
features, such as albumin and apolipoprotein B expression
and secretion, urea secretion, low-density lipoprotein (LDL)
uptake, glycogen storage, and functional bile transport.25e28
However, to evaluate hiPSC differentiation toward HLCs,
an important prerequisite needs to be formulated. Which
hepatocytes are we talking aboutdhepatocytes in liver tis-
sue or in vitro cultured hepatocytes? What is the phenotype
of a primary human hepatocyte in vitro? Undoubtedly, this
phenotype is different from that of a hepatocyte in vivo. The
phenotype of primary human hepatocytes evolves over time
in culture. After plating, the expression of a panel of hep-
atospeciﬁc genes decreases without signiﬁcant modiﬁcation
of hepatocyte viability, which is a consequence of the
adaptation of primary human hepatocytes to cell culture
conditions. Despite this modiﬁcation in gene expression,
some hepatic functions are maintained over time, such as
protein secretion (albumin and a1-antitrypsin),
29 cyto-
chrome (CYP) P450 induction and activity,30 nuclear re-
ceptor expression31 and functionality,30 blood clotting factor
secretion, 32 and apolipoprotein synthesis.29,31
Can we hope to obtain HLCs with a phenotype close to
hepatocytes in vivo despite the fact that fully mature hepato-
cytes quickly lose many functions when maintained in vitro?
This issue has only been partially resolved once with the
HepaRG cell line, which acquires certain hepatocyte functions
after in vitro differentiation.33 Indeed, a comparison between
differentiated HepaRG and primary human hepatocytes
demonstrated that HepaRG cells are a suitable model for
pharmaceutical studies (drug metabolism, CYP regulation,
and hepatotoxicity) but have a low rate of urea production.34,35The American Journal of Pathology - ajp.amjpathol.orgCriteria that allow for the characterization of the differ-
entiated phenotype of HLCs need to be clearly formulated
by the scientiﬁc community. Such criteria have previously
been proposed by Hengstler et al36 and include albumin,
urea, and ﬁbrinogen synthesis, phase 1 and 2 metabolic
enzyme activity (with speciﬁc substrates), and induction of
drug metabolism enzyme and transporter (DMET) expres-
sion in response to speciﬁc inducers. This question has also
been addressed by Snykers et al37 and Sancho-Bru et al,38
who proposed a number of recommendations to stan-
dardize in vitro production of HLCs.
Protocol Reproducibility
During the last 5 years, the ﬁeld has witnessed the publication
of several hiPSC differentiation protocols that mimic devel-
opmental processes and lead to HLCs with increasing
efﬁciency,25e28 whose results have recently been summa-
rized39,40 (Table 1). To characterize differentiated cells, the
most commonly measured hepatic functions were albumin
secretion, urea synthesis, glycogen storage, LDL uptake, and
detoxiﬁcation. However, the comparison of HLC phenotypes
among different studies remains difﬁcult. Besides the fact that
different cell lines were used and that differentiation protocols
vary from one study to another, methods and controls used to
evaluate hepatic functions were extremely different, which can
be an issue for their reproducibility. This can be illustrated by
the evaluation of a simple parameter, albumin secretion. After
differentiation, secreted albumin was frequently measured by
ELISA, but results were expressed in many different forms: as
quantity per volume (with results ranging from 60 to 350 ng/
mL), as quantity per volume per day or quantity per protein
content per day, as fold change per nondifferentiated cells, or as
arbitrary units. Others have expressed this result as a percentage
of albumin secretion by primary human hepatocytes, whereas
this secretion is dependent on primary human hepatocytes
quality, which can vary according to age of the liver donor, the
pathophysiologic status of the liver, and culture conditions and
duration.67 Ideally, data should be expressed as quantity per
time per number of cells or quantity of protein to standardize
results from different laboratories. It is therefore currently
almost impossible to compare protocols performed in different
laboratories based on albumin secretion or other liver function
parameters. To date, the improvement of differentiation pro-
tocols can thus only be evaluated within the same laboratory.
Improvement and Maintenance of HLC Phenotypes
The liver is a highly metabolic tissue organized in a spatially
complex architecture that is composed of functional and
morphologic interacting compartments. The lobule, deﬁned
as the functional liver unit, is characterized by a periportal to
centrilobular zonation that allows the liver to assume >500
functions.68 This architecture deﬁnes cell-cell contacts,
paracrine signaling, and oxygen and nutrient gradients.
Differentiation protocols applied to either hiPSCs or human335
Table 1 Summary of Pluripotent Stem Cell Differentiation Protocols Toward Hepatocyte-Like Cells
References iPS cell source
Reprogrammation Protocol
features
In vitro
functional assays
Comparison
with PHH
In vivo
assaysGenes Method
Sullivan et al28 Fibroblasts OKSM Retrovirus Sequential GF AFP, TTR, fibronectin,
fibrinogen secretion,
CYP1A2 and CYP3A4
activity
No No
Song et al27 Fibroblasts OKSU Lentivirus Sequential GF ALB and Urea secretion,
glycogen storage, CYP450
activity
Yes No
Si-Tayeb et al26 Fibroblasts OLSN Lentivirus Sequential GF
Hypoxia
ALB and urea secretion,
glycogen storage, ICG
and LDL uptake, Oil red O
staining
No Newborn CD1
Liu et al41 Adult hepatocytes OKSM Retrovirus Sequential GF Glycogen storage, CYP1A2
and CYP3A4 activity
No No
Rachid et al42 Dermal fibroblasts
with A1ATD, GSD,
FH, CN or HT1
OKSM Retrovirus Sequential GF ALB secretion, LDL uptake,
glycogen storage, CYP450
activity
No No
Touboul et al43 Foreskin Fibroblast OKSM Retrovirus Sequential GF Glycogen storage, LDL and
ICG uptake, CYP3A7
activity
No uPA/RAG2/
Ghodsizadeh
et al44
Dermal Fibroblasts
with PFHC, HT,
GSD, or CN
OKSM Retrovirus EB Sequential GF ALB, urea and AFP
secretion, LDL and ICG
uptake, glycogen
storage, CYP450 activity
No No
Liu et al45 Adult hepatocytes
Liver fibroblasts
BM-MSC
Keratinocytes
OKSM Retrovirus Sequential GF ALB secretion, CYP450
activity
Yes NOD-SCID IL2R
Chen et al46 Dermal fibroblasts OKSM Retrovirus Sequential GF HGF CYP3A4 activity, urea
secretion, LDL uptake,
glycogen storage
Yes NOD-SCID CCl4
Inamura et al47 Lung fibroblast cell
line
OKSM Retrovirus Sequential GF
Ad-Hex
CYP3A4 activity, RIF
induction
Yes No
Joczefczuk et al48 Neonatal foreskin
fibroblasts
OKSM Retrovirus Sequential GF
NaBu
Urea secretion, PAS
staining, ICG uptake
Yes No
Takata et al49 Fibroblasts OKSM Lentivirus Sequential GF ALB and urea secretion,
CYP3A4 activity, PAS
staining
No No
Takayama et al50 Lung fibroblast cell
line
OKSM Retrovirus Sequential GF Ad-
SOX17, Ad-HEX
Yes No
Takayama et al51 Lung fibroblast cell
line
OKSM Retrovirus Sequential GF
Ad-SOX17, Ad-
HEX Ad-HNF4
CYP3A4, CYP1A2, CYP2C9
activity, RIF and OM
induction, PAS staining,
ICG uptake, drug induced
toxicity
Yes No
Takayama et al52 Lung fibroblast cell
line
OKSM Retrovirus Sequential GF
Ad-SOX17, Ad-
HEX Ad-HNF4
Ad-HNF1a/b,
Ad-Foxa2, Ad-
HNF6
ALB and urea secretion, PB,
RIF and bNF induction,
CYP1A2, CYP 2B6,
CYP2C8/9/19, CYP2D6,
CYP3A4 activity, UGT
activity, ICG uptake, drug
induced toxicity
Yes No
Kajiwara et al23 Dermal fibroblasts OKSM OKS Retrovirus Sequential GF
NaBu
ALB secretion, ammonia
clearance
No No
Nagamoto et al53 Lung fibroblast cell
line Dermal
fibroblasts
OKSM Retrovirus Sequential GF
co-culture
stratification
Ad-Foxa2,
Ad-HNF1a
ALB secretion No No
(table continues)
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Table 1 (continued )
References iPS cell source
Reprogrammation Protocol
features
In vitro
functional assays
Comparison
with PHH
In vivo
assaysGenes Method
Nakamura et al54 Adult Skin
Fibroblasts
OKSM Retrovirus Sequential GF ICG uptake, PAS staining,
CYP3A4 activity
No No
Woo et al55 Fibroblasts OKSM Retrovirus EB, Sequential GF
ICGþ cell sorting
ALB and urea secretion No Nude mice CCl4
Ma et al56 Wi Cell cell line NA NA Sequential GF ICG uptake, PAS staining,
RIF and PB induction,
ALB secretion, bufuralol
metabolism
Yes NOD/SCID
Takayama et al57 Lung fibroblast cell
line
OKSM Retrovirus Sequential GF Ad-
Foxa2, Ad-
HNF1a, 3D
ALB and urea secretion, CLF
import and efflux, CYP2C9
and CYP3A4 activity, RIF
induction, drug induced
toxicity
Yes No
Ulvestad et al58 Dermal Fibroblasts OKSM Lentivirus Cellartis protocol PAS staining, CYP1A,
CYP2B6, CYP2C9, CYP3A4,
OATP1B1, NTCP, BSEP
activities
Yes No
Vosough et al59 Fibroblasts OKSM Retrovirus Spheroids
sequential GF
dynamic
conditions
PAS staining, ICG uptake,
PROD metabolism, ALB
and urea secretion, Dil-
LDL uptake
No NMRI mice CCl4
Yanagida et al60 Dermal Fibroblasts OKSM Retrovirus Sequential GF
spheroids
ALB production No No
Stevens et al61 NA NA NA Sequential GF co-
culture
micropatterning
ALB production Yes No
Shan et al62 NA NA NA Sequential GF
small molecules
ALB and AFP production,
CYP2A6 and CYP3A4
activity
Yes No
Takebe et al63 Dermal fibroblasts OKSM Retrovirus Sequential GF co-
culture
organoids
ALB production* Yes NOD/SCID TRECK/
SCID TK-NOG
Medine et al64 Fibroblasts OKSM Retrovirus Sequential GF
polyurethane
substrate
CYP2C9 activity, drug
induced toxicity
Yes No
Krueger et al65 Dermal fibroblasts OKSM Lentivirus Sequential GF Cholesterol secretion, statin
activity
Yes No
Ogawa et al66 Fibroblasts OKSM Retrovirus Sequential GF
aggregation
cAMP
ICG uptake, glycogen
storage, ALB production,
CYP3A4 and CYP1A2
activity (HPLC metabolite
detection)
Yes No
*In vivo detailed functional validation.
A1ATD, a1-antitrypsin deﬁciency; Ad, adenovirus; ALB, albumin; bNF, b-naphthoﬂavone; BM-MSC, bone marrow mesenchymal stem cells; BSEP, ATP-binding
cassette, subfamily B (MDR/TAP), member 11; EB, embryoid bodies; CLF, choly-lysyl-ﬂuorescein; CN, Crigler-Najjar syndrome; FH, autosomal-dominant mu-
tation in LDL receptor; HPLC, high-performance liquid chromatography; HT1, hereditary tyrosinemia type 1; GF, growth factors; GSD, glycogen storage disease;
K, KLF4; M, cMyc; NA, not available; NaBu, sodium butyrate; NMRI, Naval Medical Research Institute; NOD/SCID, diabetic/severe combined immunodeﬁcient;
NTCP, solute carrier family 10 (sodium/bile acid cotransporter family) member; OATP1B1, solute carrier organic anion transporter family, member 1B1; OM,
omeprazole; O, OCT4; PB, phenobarbital; PFHC, progressive familial hereditary cholestasis; PROD, pento-resoruﬁn-O-dealkilase; RIF, rifampicin; S, SOX2; TK-
NOG, thymidine kinaseeNOG; TRECK, toxin receptoremediated cell knockout; TTR, transthyretin; U, Utf1; uPA/RAG2/, urokinase-type plasminogen acti-
vator/recombination activating gene 2.
Human Induced Pluripotent Stem Cellsembryonic stem cells (hESCs) attempt to recapitulate liver
ontogeny to obtain parenchymal hepatic cells. The actual
consensus is that generated HLCs possess a fetal phenotype.
Maturation toward a fully adult phenotype is therefore yet to
be achieved. Moreover, once the differentiated phenotype is
obtained, it must be maintained over time.The American Journal of Pathology - ajp.amjpathol.orgOverexpression of Transcription Factors
Liver development is regulated by a coordinated, dynamic,
and sequential activation of transcription factors.69 In the
early liver differentiation stage, SOX17,70 hematopoietically
expressed homeobox (HEX),71 and HNF3b (FOXA2)72337
Gerbal-Chaloin et alhave been reported to play essential regulatory roles. Sub-
sequently, several liver enriched transcription factors are
key components of the liver differentiation process,73,74
such as HNF-1, HNF-4, HNF-6, and CCAAT/enhancer
binding protein families. Among them, HNF-4 has been
reported to bind to nearly half of the hepatic genes.75
However, the HNF4a family is complex, and the expres-
sion of different HNF4a transcripts varies during develop-
ment. The HNF4-a7 isoform is mainly expressed in fetal
liver, whereas the HNF4-a1 isoform is predominant in adult
mouse or human hepatocytes.76,77
Sequential forced expression of transcription factors has
therefore been used to improve HLC phenotype differenti-
ation in vitro. Deﬁnitive endoderm fate was improved using
adenovirus-mediated SOX17 overexpression in hESC- and
iPSC-derived mesendoderm cells.50 Similarly, adenovirus-
HEX transduced deﬁnitive endoderm cells efﬁciently
generated hepatoblasts.47 Hepatic maturation was therefore
achieved by the sequential adenovirus-mediated expression
of SOX17, HEX, and HNF4a.51 In these conditions, 80% of
HLCs expressed the hepatospeciﬁc asialoglycoprotein re-
ceptor 1 and presented a drug metabolic proﬁle close to that
of primary human hepatocytes. Lentiviral mediated over-
expression of the mature hepatic nuclear receptor constitu-
tive androstane receptor was also used by Funakoshi et al78
to improve the ﬁnal drug metabolism phenotype of HLCs.
Finally, direct conversion of mouse ﬁbroblasts to HLCs was
achieved by overexpression of a cocktail of lineage-speciﬁc
transcription factors, including Hnf4a plus Foxa1, Foxa2, or
Foxa379 or Gata4 plus Hnf1 and Foxa3.80
Because of the difﬁculty in obtaining a fully mature HLC
phenotype in vitro, the overexpression of hepatic regulatory
gene network effectors (transcription factors and nuclear
receptors) or hepatic speciﬁc metabolic effectors (CYPs) is a
promising technique for achieving maturation of HLCs.64
Mimicking Modiﬁcation That Occurs during Neonatal
and Postnatal Life
At birth, the liver is affected by numerous physiologic modi-
ﬁcations. Some hepatic functions reach an adult level during
the fetal period (urea, cholesterol, apolipoprotein, and albumin
synthesis), whereas other functions are stimulated after birth.81
Portal blood ﬂow and oxygenation increase when the ductus
venosus closes naturally during the ﬁrst week of life. This
event is essential for obtaining a full maturation process.82
During the ﬁrst days of life, glycogen stores are used to
perform neoglucogenesis to compensate for reduction of the
supply of maternal glucose. This is accompanied by an in-
crease of circulating glucagon, adrenalin, and noradrenalin and
an increase of glucose-6-phosphatase activity. Food intake
also stimulates fatty acid oxidation. DNA demethylation that
occurs around birth in animalmodels also seems to be essential
for adult liverespeciﬁc gene expression.83
Xenobiotic metabolism is one of the most variable
functions during the postnatal period. Global CYP450338protein content increases from 0.3 to 0.5 nmol/mg micro-
somal protein. Sulfation and glucuronidation are the pre-
dominant functions for phase 2 enzymes in infants, and an
adult phenotype is not acquired until 12 years of age, under
the inﬂuence of hormonal factors. Conjugation activity is
low at birth but reaches adult levels within 2 weeks,
allowing for bilirubin elimination.
Physiologic modiﬁcations in the neonatal period and
during adolescence seem to play a major role in the matu-
ration of liver functions. The underlying mechanisms are not
well known, but in vitro differentiation of hiPSCs offers an
interesting model to further investigate the progression of
liver maturation.81
Co-Culture of HLCs with Other Hepatic Cell Types:
Toward a 3D Organization
Recreating the spatial organization of the liver in vitro is
essential to establish proper cell-cell/cell-matrix interactions
and hepatocyte polarity, which allows for the correct func-
tioning of the liver.84 Despite many efforts from the scientiﬁc
community, the absence of in vitro conditions, allowing for
the maintenance of a stable primary human hepatocytes
phenotype, remains problematic. Recent data from Khetani
and Bhatia85 optimized a microscale architecture that main-
tains some hepatocyte phenotypic functions for several
weeks. Similarly, three-dimensional (3D) co-culture of adult
hepatocytes with liver sinusoidal endothelial cells (LSECs)
simultaneously maintained both phenotypes.86 These strate-
gies have started to be applied to HLCs derived from hESCs
or hiPSCs. HLC albumin secretion was found to be main-
tained 2 weeks longer in a 3D conformation on a Nanopillar
Plate than in two-dimensional conditions,57 and a gain of
maturation was observed when HLCs were cultured in 3D
co-culture with type I collagen and Swiss 3T3 cell sheets.53
New approaches for complex tissue organization were
recently reported. Endothelial and stromal cells co-cultured
with HLCs favor their maturation by paracrine or cell-cell
contacts, respectively.61 Activated macrophages were
recently found to stimulate hepatic progenitor maturation
through Wnt/Numb signaling,87 although such an approach
has not yet been tested on differentiated hiPSCs. Recently,
Shan et al62 designed a high-throughput screening strategy to
identify molecules that were able to promote human hepa-
tocyte proliferation (essentially evaluated using hepatocytes
isolated from a 1-year-old donor) and/or hiPSC-derived HLC
maturation. Among >12,400 small molecules tested, two
compounds were found to improve hiPSC-derived HLC
maturation, which displayed higher expression and secretion
of albumin, lower expression and secretion of AFP, and
higher CYP2A6 and CYP3A4 activities when compared with
nontreated HLCs, and gene expression proﬁle of 83 hepatic
genes closer to adult hepatocytes than to fetal hepatocytes.
However, the lack of information concerning controls used
(age of donors, culture conditions, and duration) makes
interpretation of these results difﬁcult.ajp.amjpathol.org - The American Journal of Pathology
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could be completely removed from whole livers by portal
infusion of soft detergents to obtain decellularized liver
scaffolds (DLSs) with a well-preserved vascular network
and a speciﬁc liver matrix. Repopulation of DLSs gener-
ated from rodent liver was recently achieved after perfu-
sion of neonate primary human and endothelial cells.88,89
Further techniques to enhance repopulation after multiple
sequential cell injections have also been published.90
Although current research focuses on DLS repopulation
with primary human hepatocytes for transplantation pur-
poses, the use of such an environment could enhance and
maintain hepatic functions of hiPSC-derived HLCs with
probably an even better efﬁciency if DLS repopulation is
performed with other hepatic cell types differentiated from
hiPSCs.
Differentiation of Other Hepatic Cell Types from hiPSCs
Most publications in the ﬁeld of hiPSC differentiation to-
ward HLCs have focused almost exclusively on hepato-
cytes. Indeed, the parenchymal fraction of the liver
consists of hepatocytes, which represent nearly 80% of the
liver volume and are in charge of most metabolic func-
tions. However, nonparenchymal cells, including LSECs,
Kupffer cells (resident macrophages of the liver), hepatic
stellate cells (HSCs), and cholangiocytes, which represent
up 6.5% of the liver volume, are essential to maintain
hepatic metabolic activities in addition to handling other
functions that are not covered by hepatocytes.67 Therefore,
designing differentiation protocols to obtain such cells
should provide new tools to understand liver development
and pathophysiology.
Mouse iPSCs can participate in the generation of all he-
patic cell types in vivo. Embryos produced with iPSCs by
tetraploid complementation have livers indistinguishable
from wild-type animals,26,91 containing hepatocytes, chol-
angiocytes, macrophages, HSCs, and LSECs, which strongly
suggests that, once reprogrammed, hepatic cell types other
than hepatocytes can be generated from somatic cells.
Hepatoblasts of the developing liver are capable of differ-
entiating toward both hepatocytes and cholangiocytes. Several
authors have thus isolated a bipotential hepatoblast population
during differentiation protocols of embryonic stem cells
(ESCs) toward hepatocytes. Cai et al92 observed a cytokeratin
7 positive (KRT7þ) population of cells after hepatic differ-
entiation of hESCs, which formed bile ductelike structures in
proximity to AFPþ and albuminþ cells. Zhao et al93 obtained a
bipotential hepatic progenitor population from hESCs after
sorting with N-cadherin at the hepatic endoderm stage and
ampliﬁcation on mouse STO feeder cells. After inclusion in a
collagen I/Matrigel mixture, cells acquired cholangiocyte
properties, forming duct-like cyst structures that contained
cells that expressed KRT7 and KRT19, with polarized
expression of b-catenin and actin. A hepatoblast-like v-kit
Hardy-Zuckerman 4 feline sarcoma viral oncogeneThe American Journal of Pathology - ajp.amjpathol.orghomologenegative and epithelial cell adhesion moleculee-
positive population (c-kit/EpCamþ) has also been isolated
after differentiation of mouse ESCs.94 These cells formed
branching structures in 3D culture conditions and expressed
biliary markers, such as Krt7, Krt19, Hnf1b, integrin b4, and
g-glutamyltransferase 1. Similarly, cholangiocyte-like cells
were observed during hepatic differentiation of hiPSCs,54
forming bile ductelike structures and releasing the bile
ductespeciﬁc enzymes g-glutamyl transpeptidase and leucine
aminopeptidase into the culture medium after a D-galactos-
amine toxicity assay. The authors also found evidence of
bipotential AFPþ/EpCamþ hepatoblasts in the culture system.
Finally, polarization of cholangiocyte-like cyst structures
differentiated from hiPSCs has recently been described.60
Endothelial cells are near hepatic cells and have found to be
essential duringmorphogenetic events that occur in early liver
development in mice.95 They also play a role during liver
regeneration through the inhibitor of DNA binding 1, domi-
nant negative helix-loop-helix proteinedependent secretion
of angiocrine factors wingless-type MMTV integration site
family member 2, and hepatocyte growth factor by LSECs on
speciﬁc depletion of vascular endothelial growth factor 2 re-
ceptor (VEGFR2).96 Altogether, these data strongly suggest
the importance of endothelial cells during hiPSC differentia-
tion and maturation. LSECs are a particular cell type because
their phenotype is closer to lymphatic endothelial cells rather
than blood vascular endothelial cells. Indeed, they were found
to express low levels of cluster CD31 and platelet endothelial
cell adhesion molecule 1, whereas the lymphatic marker
lymphatic vessel endothelial hyaluronan receptor 1 and sta-
bilin 2 were highly expressed. In addition, they possess a poor
basal lamina and loose tight junctions and are highly fenes-
trated.24 hiPSC differentiation toward LSECs has not yet been
described, although differentiation toward endothelial cells
capable of forming functional blood vessels has been reported
and could provide a good starting point to obtain LSECs.97
The differentiation of HSC from hiPSCs appears to be
more challenging because their origin is not completely
understood. Recent liver development and lineage tracing
studies indicate that HSCs are derived from the mesothelial
sheet that surrounds the developing liver bud.98 Therefore,
conditions to efﬁciently differentiate hiPSCs toward a
mesothelium, which is derived from the mesoderm, should
ﬁrst be established to pursue toward HSCs. This step could
be facilitated by comparative analysis with the existing
hepatic stellate cell line LX2.99,100
Finally, although Kupffer cell differentiation has not yet
been reported, it has been reported that the generation of
macrophages from hESCs and hiPSCs is possible.101,102
Applications of hiPSCs in Hepatology
Developmental Studies
Many animal models were and will remain useful for the study
of liver development, and because hiPSC differentiation339
Gerbal-Chaloin et altoward hepatic cells recapitulates established developmental
steps, this particular model provides a precious tool to dissect
these events in humans. The Duncan group published a proof-
of-concept study after silencing the expression of HNF4a in
hESCs, demonstrating that the endoderm differentiated from
the silenced hESC line failed to specify into a hepatic fate and
further differentiate into HLCs103 as was previously demon-
strated during mouse development.104
More recently, Han et al105 have reported the role of kinase
insert domain receptor (a type 3 receptor tyrosine kinase)
(Kdr)(Vegfr2)þ/CD31þ endothelial cells in hepatic speciﬁ-
cation and hepatic endoderm expansion via the Wnt and
Notch pathways in mouse ESCs. The same group demon-
strated using hESCs that human hepatic speciﬁcation was
enabled by KDRþ/CD31 endodermal cells rather than the
cell population previously described in mice.106 In addition
to revealing this species-related difference, their study
described for the ﬁrst time a hepatic endodermal population
expressing KDR, previously considered as a mesodermal
marker, capable of differentiating into cholangiocytes and
hepatocytes and able to support the hepatitis C virus (HCV)
life cycle once differentiated into HLCs. More importantly,
these results generated from hESC differentiation were
conﬁrmed by analysis of human fetal livers and mouse liver
development, which considerably strengthens the importance
of this developmental model. Indeed, observations made by
Goldman et al106 in mice were not initially concordant with
those made by Ding et al96 in Vegfr2 Green ﬂuorescent
protein mice, where Green ﬂuorescent protein was reported
to be exclusively expressed in LSECs. In addition, part of
their results were generated using an inducible Rose-
CreERT2/Vegfr2ﬂox/ﬂox mouse model that leads to Vegfr2
knockout in all cells, which in light of the results of the study
by Goldman et al,106 may be not solely due to defects in
LSECs. However, LSEC-speciﬁc angiocrine factors and the
role of the inhibitor of DNA binding/differentiation protein-1
(Id-1) in their induction during liver regeneration were
further described in an inducible vascular endotheliale
cadherineCreERT2/Vegfr2ﬂox/ﬂox mouse model, which leads
to Vegfr2 knockout in endothelial cells.
Whereas these studies use hESCs, patient-speciﬁc
hiPSCs will without doubt be useful in studying develop-
ment. A direct application can be illustrated by recent work
from Cui et al,107 which highlights the role of glypican-1
(GPC1) and hedgehog signaling in biliary atresia. The au-
thors performed a genome-wide association study that led
to the identiﬁcation of GPC1, coupled with a study on
zebraﬁsh to evaluate the role of GPC1 in biliary develop-
ment. The role of GPC1 and Hedgehog signaling in early
hepatic development could be studied in humans on
patient-derived hiPSC differentiation.
Disease Modeling
The possibility of generating hiPSCs from all types of do-
nors has allowed researchers to access the HLCs from340patients with inherited metabolic disorders to set up models
in a human context and develop platforms to test molecules
with therapeutic potential. Several inherited metabolic dis-
order models have already been published, including a1-
antitrypsin deﬁciency, glycogen storage deﬁciency, Wilson
disease, and autosomal-dominant hypercholesterolemia
among others.108 However, although proof-of-concept
studies have established that major disease phenotypes can
be reproduced in vitro, further analysis of mechanisms un-
derlying the diseases is usually lacking.
For instance, autosomal-dominant hypercholesterolemia
leads to serious and premature cardiovascular complications
due to elevated levels of circulating LDL cholesterol (LDL-
C) because the liver fails to recycle LDL-C after interaction
with its receptor. Current autosomal-dominant hypercholes-
terolemia models developed from hiPSCs focus only on pa-
tients with LDL receptor mutations. Although most of the
published data only demonstrate the inability of HLCs to
uptake LDL (as discussed by Siller et al105), Cayo et al109
further found that differentiated cells were able to respond
to statin treatments, the most efﬁcient pharmacologic
approach to reduce LDL-C levels, and overproduced apoli-
poprotein B100/very LDL in the extracellular medium
compared to healthy controls, reproducing clinical observa-
tions. However, it is not clear yet if this overproduction was
due to a decrease of apolipoprotein B100 intracellular
degradation or a defect in its recapture due to low levels of
LDL receptor at the cell membrane. Such a speciﬁc disease
model may allow for a more detailed analysis of intracellular
cholesterol homeostasis, bile synthesis, and triglyceride-
cholesterol ratios in secreted very LDL particles to better
understand pathophysiology and to identify new potential
therapeutic targets.
Host-Pathogen Interactions: HCV, Hepatitis B Virus,
and Parasites
The major limitation of HCV host interaction studies is the
lack of cellular models accurately mimicking physiologic
events. Since 2005, the most popular system associates
hepatocellular carcinoma cell lines (Huh-7 and derivatives)
and a limited number of viral sequences, mainly the JFH1
strain (genotype 2a). Although all these systems represent
valuable tools, the hepatoma cell phenotype differs greatly
from that of healthy human adult hepatocytes.110,111
Moreover, natural serum-derived HCV presents several
different genotypes, subtypes, and quasi-species, which
sharply contrast with viruses produced in culture.112 In that
respect, fetal or adult primary human hepatocytes are the
most relevant system, allowing for the study of the entire
viral cycle, using either viruses produced in culture particles
and derivatives113e119 or HCV-positive serum samples from
chronically infected patients.120e122
Since 2011, hESCs or hiPSCs differentiated toward HLCs
have emerged as new cell culture models for HCV studies.
The hiPSC-derived HLCs were reported to express keyajp.amjpathol.org - The American Journal of Pathology
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122, and have been found to be susceptible to HCV pseu-
dotyped virus and HCV subgenomic replicons.123 Using a
viruses produced in culture reporter viruseexpressing
secreted Gaussia luciferase, Schwartz et al124 have reported
that HLCs derived from hiPSCs support the entire life cycle
of HCV, including inﬂammatory responses to infection. The
persistent infection of HLCs (derived from both hESCs and
hiPSCs) was conﬁrmed using viruses produced in culture,
and the critical importance of cellular cofactors for HCV
replication was reported.125,126 Interestingly, Wu et al126
have identiﬁed a transition point during the differentiation
process at which cells became permissive to HCV.Moreover,
the differentiated cells could be infected with HCV patient
sera (genotypes 1a and 1b), a key feature that is shared only
with mature primary human hepatocytes. The effectiveness
of HLC infection compared with that of the primary human
hepatocytes remains to be precisely determined using a panel
of HCV-positive sera of different genotypes under controlled
culture conditions. Indeed, parameters, including medium
composition, day of inoculation after seeding, and time
course of infection, are critical for the evaluation of cell
permissivity (Gondeau et al, unpublished data). Overall,
these ﬁndings demonstrate the functionality of hiPSC-
derived HLCs and are, together with primary human hepa-
tocytes, the best alternative approach for HCV studies.
Interestingly, these cells offer the opportunity to explore the
inﬂuence of host genetic factors on viral pathogenesis and
treatment response127 and enable the generation of human-
ized mice as in vivo models for investigation of hepatic viral
infections (HCV or hepatitis B virus).128 Strategies using
HLCs should also allow for further investigations on theFigure 3 A: Current strategies for hepatocyte-like cells (HLC) maturation. 1:
culture and use of small molecules. 3: Co-culture of speciﬁed hepatic endoderm
3D environment leads to the generation of a self-organized liver organoid that is
will provide an accurate model for disease modeling and drug detoxiﬁcation stu
provided by DLSs may facilitate hiPSC-derived HLC implantation, proliferation, and
probably a promising approach to improve and maintain maturation. 3: The com
derived HLCs in large quantities through serial repopulation of FRG mouse livers
The American Journal of Pathology - ajp.amjpathol.orgmechanisms of host-parasite interaction (ie, Plasmodium
falciparum and P. vivax).129
Drug Metabolism and Toxicity
One of the keymetabolic functions of the liver is detoxiﬁcation
via the DMET network, which is also an important effector of
drug-induced toxicity. On one hand, the bioactivation of
certain compounds can lead to the production of reactive
metabolites, which can be toxic; on the other hand, drugs can
alter the DMET network, therefore leading to changes in
pharmacokinetic parameters or drug-drug interactions. The
detoxiﬁcation process is therefore a balance between the
elimination of xenobiotics and the production of toxic me-
tabolites. To date, primary human hepatocytes cultures are the
gold standard model to evaluate drug metabolism and toxicity,
and HLCs are promising new tools, provided that the complex
and highly regulated network of DMET proteins and xen-
osensors are expressed and functional. This aspect has recently
been reviewed by Kia et al,130 who emphasized the difﬁculty
in judging the quality of data due to the lack of adapted,
characterized, and standardized controls.
Most published studies evaluate CYP mRNA expression,
with certain studies comparing their expression to levels in
primary human hepatocytes. Few studies analyze CYP
expression on the protein level, and only a few of them
compared HLC metabolic activity to primary human hepa-
tocytes. The metabolic activity of P450-3A4 in HLCs has
been reported to be equivalent to that of primary human
hepatocytes45,46 when measured with a luminescent sub-
strate (P450-Glo). However, P450-3A4 activity was only
threefold higher in HLCs versus hiPSCs in the study ofhiPSC differentiation toward HLCs. 2: Maturation of HLCs through 3D co-
(SHE) with endothelial cells (EC) and mesenchymal stem cells (MSC) in a
metabolically active after transplantation. 4: Enhanced differentiated HLCs
dies. B: Perspective of HLC maturation. 1: The extracellular environment
maturation. 2: Repopulation of decellularized livers with liver organoids is
bination of recent breakthroughs may facilitate the production of hiPSC-
and could allow for the development of new bioengineered livers.
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Gerbal-Chaloin et alChen et al,45 emphasizing a lack of substrate speciﬁcity. The
3D cultured HLCs were found to be predictive of drug-
induced hepatotoxicity,57 again in a less sensitive manner
than primary human hepatocytes. Induction of P450-2B6
activity was observed by Song et al27 in response to the
prototypical inducer phenobarbital, but this activity was
much lower than that of primary human hepatocytes.
Finally, using small molecules to improve HLC differenti-
ation at day 20, Shan et al62 observed signiﬁcant increase of
P450-3A4 and P450-2A6 activities, in parallel to a global
maturation process.
It is clear that despite many advances in the ﬁeld, it is not
yet completely possible to use HLCs to screen drug meta-
bolism or toxicity. Differentiation protocols and methods for
analyzing drug metabolism functionality need to be
improved. The simultaneous quantiﬁcation of the activity of
major CYPs and certain phase 2 enzymes and transporters is
possible with ultraperformance liquid chromatography and
tandem mass spectrometry, using a cocktail of DMET
substrates.131 Moreover, multiple reaction monitoring tech-
nology is a promising way to simultaneously perform rela-
tive or absolute quantiﬁcation of multiple target proteins.
This highly sensitive technique helps avoid misinterpreta-
tion because of the lack of speciﬁcity and sensitivity of
certain antibodies.132
Clinical Perspectives
Cell transplantation of hiPSCs differentiated toward HLCs
theoretically offers a precious alternative to orthotopic liver
transplantation for liver failure because there is a current
shortage of donor organs. To test suitable cell trans-
plantation conditions, several models that evaluate HLC
liver repopulation are available. Among them, Grompe and
colleagues133 developed an immunodeﬁcient mouse model
(Rag2/; common g-chain of the interleukin receptor/)
deﬁcient for defumaryl acetoacetate hydrolase (FRG mice).
In the absence of this enzyme, which is involved in the
tyrosine catabolism, FRG mice develop serious liver failure
unless they are provided with a protective drug. This model
was successfully repopulated by primary human hepato-
cytes,134 and in vivo functionality was further demonstrated
by their permissivity to HCV and hepatitis B virus infec-
tion.134 Moreover, efﬁcient repopulation of the liver of FRG
mice by mouse iPSC-derived HLCs was demonstrated in the
same model.91 However, no conﬁrmed reports to date have
indicated that hiPSC-derived HLCs are capable of repopu-
lating a mouse liver, suggesting that their level of maturity is
not yet sufﬁciently advanced to ensure rodent metabolic
functions.
An interesting approach was suggested by Takebe et al,135
who recapitulated liver organogenesis in vitro, forming a
liver organoid with a mixture of human fetal hepatocytes and
human mesenchymal and endothelial cells in a matrix that
naturally evolved toward a self-organized structure. On the
basis of their initial ﬁndings, the same group recently published342a proof-of-concept study reporting that hiPSC-derived speci-
ﬁed hepatic endoderm co-cultured with human umbilical
vascular endothelial cells and human mesenchymal stem cells
in a 3D matrix could self-organize into liver organoids (hiPSC-
LOs), thus providing an environment that enhanced HLC dif-
ferentiation.136 Human liver organoids generated in vitro were
metabolically active after ectopic transplantation and could
rescue mice on induced liver failure. This is the ﬁrst time, to our
knowledge, that hepatic functions were performed in vivo with
HLCs differentiated from hiPSCs, and such amodel opens new
opportunities for research and preclinical studies.
First, it will now be possible to analyze cell signaling and
interactions during in vitro liver organoid formation to
provide a better understanding of early stages of liver
organogenesis in humans. Several questions need to be
answered: are endothelial cells acquiring LSEC phenotypes?
Is there a biliary tree rudiment developing in the hiPSC-
LOs? Can we detect HSC possibly emerging from mesen-
chymal stem cells? Do hiPSC-LOs develop an equivalent of
the Glisson capsule?
Second, because it seems that hiPSC-LOs further differ-
entiate after transplantation and can support in vivometabolic
functions, HLCs isolated from transplanted hiPSC-LOs may
provide a suitable source of cells to repopulate livers of FRG
mice, which will considerably amplify the number of ho-
mogeneous and well-differentiated patient-speciﬁc HLCs.
Finally, one can imagine that for clinical purposes, the
ectopic transplantation of several hiPSC-LOs in patients with
critical disease may help to sustain hepatic functions until
liver transplantation. However, it is difﬁcult to conceive that
hiPSC-LOs could be used for orthotopic liver transplantation
because it has not been reported that they can recapitulate full
liver organogenesis, which includes, for instance, the
development of a biliary system that collects bile and stores it
in the gallbladder and a vascular network able to gather blood
ﬂow from the hepatic artery and the hepatic portal vein.
However, recellularized DLSs were found to keep rats alive
for several hours after transplantation, suggesting that DLSs
offer an ideal environment to preserve hepatocyte func-
tions.137,138 In addition, a human-scale whole organ bioen-
gineering approach for liver transplantation was recently
published after attempting the repopulation of porcine
decellularized livers.139 This continuously developing tech-
nology combined with the ﬁndings of Takebe et al63,135 may
lead to a new kind of bioengineered liver that will better meet
clinical expectations.Conclusion
Differentiation of hiPSCs toward HLCs continues to hold
great promise for applications in hepatology, and recent
publications have demonstrated that many research groups
worldwide are displaying creative and original strategies to
move the ﬁeld forward. These advances are gradually
overcoming the original limitations of this model and areajp.amjpathol.org - The American Journal of Pathology
Human Induced Pluripotent Stem Cellsbringing us closer to their efﬁcient use for liver development
studies, disease modeling, drug toxicity studies, and ulti-
mately therapeutic and clinical applications (Figure 3).References
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